MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from maturitiesof...$25,552K Proceeds from exercisesof stock options$222K Net cash provided by(used in) investing...$16,965K Net cash provided byfinancing activities$222K Canceled cashflow$8,587K Net increase(decrease) in cash and cash...$498K Canceled cashflow$16,689K Purchases ofavailable-for-sale marketable...$8,485K Purchases of property,equipment and leasehold...$102K Stock-based compensation$2,191K Operating leaseright-of-use assets$105K Depreciation andamortization$34K Net cash used inoperating activities-$16,689K Canceled cashflow$2,330K Net loss-$13,192K Prepaid expenses andother current assets$2,838K Accounts payable-$1,483K Accrued expenses andother liabilities-$1,075K Accretion ofavailable-for-sale marketable...$431K
Cash Flow
source: myfinsight.com

Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics, Inc. (TRVI)